Applicants: Gregory B. Wilson et al.

Serial No.: 09/776,010 Filed: February 2, 2001

Page 2

1.5

## Listing of Claims

## 1-31. (Canceled)

- 32. (Previously Presented) A cell-free fluid consisting essentially of a mammary gland secretion of a human herpesvirus-6A immunized lactating mammal.
- 33. (Previously Presented) A cell-free fluid consisting essentially of a mammary gland secretion of a human herpesvirus-6B immunized lactating mammal.
- 34. (Previously Presented) The cell-free fluid of claim 32, wherein the mammal is bovine.
- 35. (Previously Presented) The cell-free fluid of claim 33, wherein the mammal is bovine.
- 36. (Previously Presented) The cell-free fluid of claim 32 in the form of a lyophilized product.
- 37. (Previously Presented) The cell-free fluid of claim 33 in the form of a lyophilized product.
- 38. (Currently Amended) A pharmaceutical composition comprising an effective amount of the cell free fluid of claim 36 32 and a pharmaceutically acceptable carrier.
- 39. (Currently Amended) A pharmaceutical composition comprising an effective amount of the cell free fluid of claim 37 33 and a pharmaceutically acceptable carrier.
- 40. (Currently Amended) A method of treating chronic fatigue

Applicants: Gregory B. Wilson et al.

Serial No.: 09/776,010 Filed: February 2, 2001

Page 3

syndrome in a human which comprises orally administering to the human an effective amount of a cell-free fluid consisting essentially of a mammary gland secretion of a human herpesvirus-6A immunized lactating mammal or of a and an amount of a cell-free fluid consisting essentially of a mammary gland secretion of a human herpesvirus-6B immunized lactating mammal, so as effective to thereby treat chronic fatigue syndrome in the human.

- 41. (Currently Canceled)
- 42. (Previously Presented) A method of treating chronic fatigue syndrome in a human which comprises orally administering to the human the pharmaceutical composition of claim 38, so as to thereby treat chronic fatigue syndrome in the human.
- 43. (Previously Presented) A method of treating chronic fatigue syndrome in a human which comprises orally administering to the human the pharmaceutical composition of claim 39, so as to thereby treat chronic fatigue syndrome in the human.
- 44. (Currently Canceled)
- 45. (Currently Canceled)
- 46. (New) A pharmaceutical composition comprising an amount of a cell-free fluid consisting essentially of a mammary gland secretion of a human herpesvirus-6A immunized lactating mammal and an amount of a cell-free fluid consisting essentially of a mammary gland secretion of a human herpesvirus-6B immunized lactating mammal effective to treat chronic fatigue syndrome in a human subject and a

Applicants: Gregory B. Wilson et al.

Serial No.: 09/776,010 Filed: February 2, 2001

Page 4

1 14

pharmaceutically acceptable carrier.

47. (New) A method of treating chronic fatigue syndrome in a human which comprises orally administering to the human the pharmaceutical composition of claim 46, so as to thereby treat chronic fatigue syndrome in the human.